Champions Oncology Inc
NASDAQ:CSBR

Watchlist Manager
Champions Oncology Inc Logo
Champions Oncology Inc
NASDAQ:CSBR
Watchlist
Price: 7.505 USD -0.6% Market Closed
Market Cap: 102m USD
Have any thoughts about
Champions Oncology Inc?
Write Note

Champions Oncology Inc
Non-Reccuring Items

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Champions Oncology Inc
Non-Reccuring Items Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Non-Reccuring Items CAGR 3Y CAGR 5Y CAGR 10Y
Champions Oncology Inc
NASDAQ:CSBR
Non-Reccuring Items
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Thermo Fisher Scientific Inc
NYSE:TMO
Non-Reccuring Items
-$231m
CAGR 3-Years
-9%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Danaher Corp
NYSE:DHR
Non-Reccuring Items
-$222m
CAGR 3-Years
-114%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Mettler-Toledo International Inc
NYSE:MTD
Non-Reccuring Items
-$30.7m
CAGR 3-Years
-52%
CAGR 5-Years
N/A
CAGR 10-Years
-11%
Agilent Technologies Inc
NYSE:A
Non-Reccuring Items
-$74m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
IQVIA Holdings Inc
NYSE:IQV
Non-Reccuring Items
-$94m
CAGR 3-Years
-30%
CAGR 5-Years
-6%
CAGR 10-Years
-26%
No Stocks Found

Champions Oncology Inc
Glance View

Market Cap
102.8m USD
Industry
Life Sciences Tools & Services

Champions Oncology, Inc. engages in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. The company is headquartered in Baltimore, Maryland and currently employs 194 full-time employees. This technology includes the Company’s in-vivo, ex-vivo and biomarker platforms, oncology software solutions, and computational-based discovery platforms. The Company’s TumorGraft Technology Platform (The Platform) provides select services to pharmaceutical and biotechnology. The Company’s software as a service business is centered around its software platform and data tool, Lumin Bioinformatics (Lumin), which contains comprehensive information derived from its research services and clinical studies. The Company’s drug discovery and development business leverages the computational and experimental capabilities within its platforms. Their discovery strategy utilizes its datacenter, coupled with artificial intelligence and other advanced computational analytics, to identify novel therapeutic targets.

CSBR Intrinsic Value
7.1 USD
Overvaluation 5%
Intrinsic Value
Price

See Also

Back to Top